Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation McGahan L. Palbociclib (IbranceĀ®) in combination with fulvestrant for the treatment of hormone-receptor-positive, HER2-negative advanced or metastatic breast cancer. Vienna: Ludwig Boltzmann Institut fuer Health Technology Assessment (LBIHTA). DSD: Horizon Scanning in Oncology. 2017 Authors' conclusions Palbociclib is a first-in-class CDK4/6 inhibitor for use in combination with fulvestrant as second-line treatment for HR-positive, HER2-negative advanced or MBC with disease progression during or following ET. While palbociclib increased median PFS by 4.9 months, this endpoint is not currently supported by OS data or clinically important differences in QoL. Physician and patient preference contribute to palbociclib's place in therapy due to the lack of OS data and head-to-head comparisons of first-line versus subsequent-line use. While the Rb protein is the only reliable indicator for palbociclib activity, further indicators and biomarkers may be of benefit for future use. Indexing Status Subject indexing assigned by CRD MeSH Breast Neoplasms; Estradiol; Humans; Piperazines; Pyridines Language Published English Country of organisation Austria English summary An English language summary is available. Address for correspondence Ludwig Boltzmann Institute fuer Health Technology Assessment (LBI-HTA), Garnisongasse 7 rechte Stiege Mezzanin (Top 20), 1090 Vienna, Austria. Tel: +43 1 236 8119 - 0 Fax: +43 1 236 8119 - 99 AccessionNumber 32017000164 Date abstract record published 04/04/2017 |